These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31836930)

  • 21. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
    Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Rafia R; Scope A; Harnan S; Stevens JW; Stevenson M; Lobo A
    Pharmacoeconomics; 2016 Dec; 34(12):1241-1253. PubMed ID: 27480631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
    Targan SR; Feagan B; Vermeire S; Panaccione R; Melmed GY; Landers C; Li D; Russell C; Newmark R; Zhang N; Chon Y; Hsu YH; Lin SL; Klekotka P
    Am J Gastroenterol; 2016 Nov; 111(11):1599-1607. PubMed ID: 27481309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
    Colombel JF; Ungaro RC; Sands BE; Siegel CA; Wolf DC; Valentine JF; Feagan BG; Neustifter B; Kadali H; Nazarey P; James A; Jairath V; Qasim Khan RM
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1487-1496.e12. PubMed ID: 37743037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
    Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
    J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety of vedolizumab for inflammatory bowel disease.
    Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
    Reinisch W; de Villiers W; Bene L; Simon L; Rácz I; Katz S; Altorjay I; Feagan B; Riff D; Bernstein CN; Hommes D; Rutgeerts P; Cortot A; Gaspari M; Cheng M; Pearce T; Sands BE
    Inflamm Bowel Dis; 2010 Feb; 16(2):233-42. PubMed ID: 19637334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
    Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
    Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.